These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 34411992)

  • 41. Seroprevalence of SARS-CoV-2 Antibodies Among Children in School and Day Care in Montreal, Canada.
    Zinszer K; McKinnon B; Bourque N; Pierce L; Saucier A; Otis A; Cheriet I; Papenburg J; Hamelin MÈ; Charland K; Carbonneau J; Zahreddine M; Savard A; Fortin G; Apostolatos A; Haley N; Ratté N; Laurin I; Nguyen CT; Conrod P; Boivin G; De Serres G; Quach C
    JAMA Netw Open; 2021 Nov; 4(11):e2135975. PubMed ID: 34812845
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
    Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies.
    Bergeri I; Whelan MG; Ware H; Subissi L; Nardone A; Lewis HC; Li Z; Ma X; Valenciano M; Cheng B; Al Ariqi L; Rashidian A; Okeibunor J; Azim T; Wijesinghe P; Le LV; Vaughan A; Pebody R; Vicari A; Yan T; Yanes-Lane M; Cao C; Clifton DA; Cheng MP; Papenburg J; Buckeridge D; Bobrovitz N; Arora RK; Van Kerkhove MD;
    PLoS Med; 2022 Nov; 19(11):e1004107. PubMed ID: 36355774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Seroprevalence of SARS-CoV-2 antibodies and associated risk factors during the second wave of infection in a university community in Cameroon.
    Essomba RG; Bayibeki AN; Lissom A; Ateba PT; Seni N; Fouda CAN; Mbitock SBD; Ebonda ND; Afana SD; Akame S; Tembu AA; Ngamaleu MR; Bimai BCB; Kabo O; Nguwoh PS; Ngounouh CT; Meka MCJ; Kengne M; Likeng JN; Kimessoukie EO; Nkoum BA; Assoumou MCO; Fokam J; Yap Boum II; Ambomo MS; Chadou MJP
    Influenza Other Respir Viruses; 2023 Nov; 17(11):e13222. PubMed ID: 37964992
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serological survey for SARS-CoV-2 antibodies among tribal communities of Odisha post-second wave.
    Kshatri JS; Bhattacharya D; Giri S; Palo SK; Kanungo S; Mansingh A; Parai D; Dany SS; Bisoyee A; Choudhary HR; Sinha A; Sahoo RK; Bhoi T; Mohanta AR; Ota AB; Mohanty B; Sahoo UK; Pati S
    Indian J Med Res; 2022 Aug; 156(2):284-290. PubMed ID: 36629188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. SARS-CoV-2 seroprevalence in hospital healthcare workers in Western Switzerland at the end of the second pandemic wave.
    Jacot D; von Rotz U; Blondet F; Aebischer O; Matthieu P; De Rham M; Pantaleo G; Marchetti O; Greub G
    J Med Microbiol; 2022 Aug; 71(8):. PubMed ID: 35921229
    [No Abstract]   [Full Text] [Related]  

  • 47. SARS-CoV-2 Seroprevalence among Healthcare Workers after the First and Second Pandemic Waves.
    de Visscher N; Holemans X; Gillain A; Kornreich A; Lagasse R; Piette P; Ventura M; Thys F
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891515
    [No Abstract]   [Full Text] [Related]  

  • 48. High prevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies among unvaccinated children of Chandigarh, Northwest India, in a household-based paediatric serosurvey post-second wave of pandemic (June to July 2021).
    Ghosh A; Goyal K; Singh R; Lakshmi PVM; Kaur R; Kumar V; Muralidharan J; Puri GD; Ram J; Singh MP
    Public Health; 2023 Dec; 225():160-167. PubMed ID: 37931485
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era.
    Reedman CN; Drews SJ; Yi QL; Pambrun C; O'Brien SF
    Microbiol Spectr; 2022 Apr; 10(2):e0033922. PubMed ID: 35412385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers.
    Gelanew T; Seyoum B; Mulu A; Mihret A; Abebe M; Wassie L; Gelaw B; Sorsa A; Merid Y; Muchie Y; Teklemariam Z; Tesfaye B; Osman M; Jebessa G; Atinafu A; Hailu T; Habte A; Kenea D; Gadisa A; Admasu D; Tesfaye E; Bates TA; Bulcha JT; Tschopp R; Tsehay D; Mullholand K; Howe R; Genetu A; Tafesse FG; Abdissa A
    BMC Infect Dis; 2022 Mar; 22(1):261. PubMed ID: 35296265
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment of initial SARS-CoV-2 seroprevalence in the most affected districts in the municipality of São Paulo, Brazil.
    Tess BH; Granato CFH; Alves MCGP; Pintão MCT; Nunes MC; Rizzatti EG; Reinach FC
    Braz J Infect Dis; 2021; 25(4):101604. PubMed ID: 34416142
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Seroprevalence and risk factors of SARS-CoV-2 infection in an urban informal settlement in Nairobi, Kenya, December 2020.
    Munywoki PK; Nasimiyu C; Alando MD; Otieno N; Ombok C; Njoroge R; Kikwai G; Odhiambo D; Osita MP; Ouma A; Odour C; Juma B; Ochieng CA; Mutisya I; Ngere I; Dawa J; Osoro E; Njenga MK; Bigogo G; Munyua P; Lo TQ; Hunsperger E; Herman-Roloff A
    F1000Res; 2021; 10():853. PubMed ID: 35528961
    [No Abstract]   [Full Text] [Related]  

  • 53. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
    Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
    BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study.
    Pollán M; Pérez-Gómez B; Pastor-Barriuso R; Oteo J; Hernán MA; Pérez-Olmeda M; Sanmartín JL; Fernández-García A; Cruz I; Fernández de Larrea N; Molina M; Rodríguez-Cabrera F; Martín M; Merino-Amador P; León Paniagua J; Muñoz-Montalvo JF; Blanco F; Yotti R;
    Lancet; 2020 Aug; 396(10250):535-544. PubMed ID: 32645347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence: Navigating the absence of a gold standard.
    Saeed S; O'Brien SF; Abe K; Yi QL; Rathod B; Wang J; Fazel-Zarandi M; Tuite A; Fisman D; Wood H; Colwill K; Gingras AC; Drews SJ
    PLoS One; 2021; 16(9):e0257743. PubMed ID: 34555095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seroprevalence of severe acute respiratory syndrome coronavirus 2 in Slovenia: results of two rounds of a nationwide population study on a probability-based sample, challenges and lessons learned.
    Poljak M; Oštrbenk Valenčak A; Štrumbelj E; Maver Vodičar P; Vehovar V; Resman Rus K; Korva M; Knap N; Seme K; Petrovec M; Zupan B; Demšar J; Kurdija S; Avšič Županc T
    Clin Microbiol Infect; 2021 Jul; 27(7):1039.e1-1039.e7. PubMed ID: 33838303
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020.
    Thompson CP; Grayson NE; Paton RS; Bolton JS; Lourenço J; Penman BS; Lee LN; Odon V; Mongkolsapaya J; Chinnakannan S; Dejnirattisai W; Edmans M; Fyfe A; Imlach C; Kooblall K; Lim N; Liu C; López-Camacho C; McInally C; McNaughton AL; Ramamurthy N; Ratcliff J; Supasa P; Sampson O; Wang B; Mentzer AJ; Turner M; Semple MG; Baillie K; ; Harvala H; Screaton GR; Temperton N; Klenerman P; Jarvis LM; Gupta S; Simmonds P
    Euro Surveill; 2020 Oct; 25(42):. PubMed ID: 33094713
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High SARS-CoV-2 seroprevalence but no severe course of COVID-19 disease among people on opioid agonist treatment in Zurich: a cross-sectional study.
    Bruggmann P; Senn O; Frei A; Puhan MA; Fehr J; Falcato L
    Swiss Med Wkly; 2022 Jan; 152():w30122. PubMed ID: 35019254
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First wave of SARS-CoV-2 in Santiago Chile: Seroprevalence, asymptomatic infection and infection fatality rate.
    Vial PA; González C; Apablaza M; Vial C; Lavín ME; Araos R; Rubilar P; Icaza G; Florea A; Pérez C; Concha P; Bastías D; Errázuriz MP; Pérez R; Guzmán F; Olea A; Guzmán E; Correa J; Munita JM; Aguilera X
    Epidemics; 2022 Sep; 40():100606. PubMed ID: 35872438
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study.
    Álvarez-Antonio C; Meza-Sánchez G; Calampa C; Casanova W; Carey C; Alava F; Rodríguez-Ferrucci H; Quispe AM
    Lancet Glob Health; 2021 Jul; 9(7):e925-e931. PubMed ID: 34022148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.